Hippocampal Hypometabolism Predicts Cognitive Decline From Normal Aging
Deerfield, ILLINOIS - - May 31, 2008 - - Researchers at New York University have published results of
a study showing their ability to predict cognitive decline years in advance of symptoms by measuring
activity in the hippocampus, a key brain region.
The results, published in the journal Neurobiology of Aging, demonstrated that glucose metabolism
in the hippocampus began to decline on an average of 8 years before Alzheimer's Disease or Mild
Cognitive Impairment occurred. The hippocampus is centrally involved in the encoding of new
memories, and has been identified as one of the first regions affected by Alzheimer's Disease and
certain other dementias. Dr. Lisa Mosconi and colleagues at New York University have developed a
unique method allowing automated measurement of hippocampal glucose metabolism from
Positron Emission Tomography (PET) images, which they applied to scans of 77 individuals
between the ages of 50 and 80, imaged over a period of 6 to 14 years.
The ability to predict cognitive decline is becoming increasingly important given an aging population,
the increasing prevalence of neurological disorders as people live longer, and the number of
promising drugs in development for treatment of dementia. Even with the drugs available today, the
opportunity for patient benefit increases when the disease is identified early in progression.
Alzheimer's Disease affects an estimated 5 million people today in the United States alone, with
another 12 million or more people in pre-symptomatic or Mild Cognitive Impairment phases of
Abiant announced previously that it has secured an exclusive worldwide license to the technology
developed at New York University that allowed the detection of these changes in the hippocampus.
Abiant, Inc. uses proprietary image analysis methods and software to provide a sensitive biomarker
of drug effects and disease progression. The imaging information, which includes biochemical,
functional, and structural measurements, can be used to accelerate or reduce risk of decision
making in both drug development and disease treatment. The Company’s focus areas include the
central nervous system, oncology, and inflammation. Further information can be found at www.
Forward Looking Statements
This press release may contain "forward-looking" statements identified by words such as “will,”
"achieve," and "enable." There are a number of important factors that could cause Abiant's results to
differ materially from those indicated by these forward-looking statements.
|Copyright 2006-2010 Abiant, Inc.
|Abiant, Inc. 480 West Center Street, Suite 202, Grayslake, Illinois 60030